Objective-Factor VII-activating protease (FSAP) activates both factor VII and pro-urokinase and inhibits platelet-derived growth factor-BB, thus regulating hemostasis-and remodeling-associated processes in the vasculature. A genetic variant of FSAP (Marburg I polymorphism) results in low enzymatic activity and is associated with an enhanced risk of carotid stenosis and stroke. We postulate that there are additional substrates for FSAP that will help to explain its role in vascular biology and have searched for such a substrate. Methods and Results-Using screening procedures to determine the influence of FSAP on various hemostasis-related processes on endothelial cells, we discovered that FSAP inhibited tissue factor pathway inhibitor (TFPI), a major anticoagulant secreted by these cells. Proteolytic degradation of TFPI by FSAP could also be demonstrated by Western blotting, and the exact cleavage sites were determined by N-terminal sequencing. The Marburg I variant of FSAP had a diminished ability to inhibit TFPI. A monoclonal antibody to FSAP that specifically inhibited FSAP binding to TFPI reversed the inhibitory effect of FSAP on TFPI. Conclusion-The identification of TFPI as a sensitive substrate for FSAP increases our understanding of its role in regulating hemostasis and proliferative remodeling events in the vasculature. (Arterioscler Thromb Vasc Biol. 2012;32:427-433.)
F actor VII activating protease (FSAP) is a protease in human plasma with a broad substrate specificity which includes hemostasis-related proteins like factor VII (FVII) and prourokinase. 1, 2 The addition of exogenous FSAP to plasma and whole blood influences coagulation and fibrinolysis. 1, 2 In vitro, the activation of FSAP is mediated by its binding to positively charged polyamines, 3 as well as negatively charged polyanions, such as heparin, RNA, and polyphosphates, resulting in a bimolecular (auto-) activation. 4 Activation of FSAP in plasma can be induced by postapoptotic/dead cells that presumably release nucleic acids, histones and nucleosomes. 5, 6 Hence, tissue damage releases nucleic acids/nucleosomes/polyamines, and platelet activation releases polyphosphates 7 which together can contribute to FSAP activation.
About 5% of the white population are carriers of a single-nucleotide polymorphism (SNP) in the FSAP gene (official name, Hyaluronic acid binding protein-2) HABP2 rs080536 that results in an exchange of a single amino acid in the protease domain (Gly534Glu). 8 The Gly534Glu polymorphism (Marburg I [MI]) is only a weak activator of prourokinase, but its ability to activate FVII is reportedly unchanged. 8 Hence, the presence of this SNP may shift the activity profile of FSAP toward a more thrombotic phenotype. This has prompted many investigations into its linkage to venous thrombosis, but with the exception of one study that did find an association, 9 the others came to an opposite conclusion. 10 -14 Other SNPs found in the HABP2 gene have a predictive value in venous thromboembolism in the elderly. 15 The MI-SNP is also linked to a higher incidence of carotid stenosis, 16 cardiovascular disease in general, 17 stroke, 18 and liver fibrosis, 19 indicating a probable role for FSAP in hemostasis, as well as remodeling processes.
We have previously shown that MI-FSAP has a lower proteolytic activity towards chromogenic substrates, prourokinase and platelet-derived growth factor-BB compared with wild-type (WT)-FSAP and that MI-FSAP did not inhibit neointima formation in vivo. 20 In contrast to previous reports that WT and MI-FSAP activate FVII equally well, 8 we found that FVII was an extremely poor substrate for WT-FSAP and not activated at all by MI-FSAP (Supplemental Data I, available online at http://atvb.ahajournals.org). These observations led us to hypothesize that there are probably other substrates for FSAP that can explain its role in vascular biology.
The primary inhibitor of the tissue factor (TF)/activated factor X (FXa)/activated FVII (FVIIa) complex is tissue factor pathway inhibitor (TFPI). 21 TFPI is produced by many cells in the vasculature, and its activity in the vessel wall is regulated in numerous ways. It is bound to the vasculature via glycosamino-glycans and can be released by heparin from intracellular stores. 22 It is also found in platelets and bound to lipoproteins, whereby the latter have a major influence on the levels of circulating TFPI. 21 TFPI consists of 3 Kunitz domains that allow it to specifically inhibit FXa and FVIIa and dampen the initiation of coagulation. The C-terminal Kunitz domain has strong propensity to bind to heparin. 21 Multiple transcriptional start sites and alternative splicing lead to expression of different forms of TFPI. 23 There is a strong species difference in the expression of these forms in that in adult humans, the predominant form is the 3-domain form called TFPI-␣, whereas a truncated transcript coding for TFPI-␤, lacking the C-terminal Kunitz domain, is expressed mainly in the adult mouse. 23 TFPI can be proteolytically inactivated by proteases such as plasmin, 24 thrombin, 25 and elastase, 26 as well as activated protein C. 27 Apart from influencing the activity of the extrinsic pathway, TFPI also regulates vascular smooth muscle proliferation 28 and has a role in innate immunity. 29 Our studies with isolated proteins and with endothelial cells show that TFPI is indeed an excellent substrate for FSAP, and this could account for the effects of FSAP in vascular as well as the extravascular compartment.
Materials and Methods

Materials
WT-and MI-FSAP, as well as Phe-Pro-Arg-chloromethylketone (PPACK)-FSAP, were isolated, prepared, and characterized as described before. 20 Single-chain FSAP zymogen is rapidly converted to the active 2-chain form within minutes at physiological pH. Recombinant full-length TFPI and truncated 2-domain TFPI(1-160) were produced as described before. 30 Anti-FSAP monoclonal antibodies (Mab 1189, 677, 570), anti-human TFPI, anti-TF polyclonal antibodies (Ab), and TFPI-depleted plasmas were from American Diagnostica (Pfungstadt, Germany). Anti-FSAP Mab MA-38C7 was produced in-house. Anti-human TFPI polyclonal Ab SC-28861 was obtained from Santa Cruz Biotechnology (Heidelberg, Germany). Tumor necrosis factor ␣ (TNF␣) was from R&D Systems (Frankfurt, Germany). Endotoxin levels in FSAP were determined using the limulus amebocyte lysate test from Biowhittaker (Verviers, Belgium).
Cell Surface FXa Generation
Cell surface functional TF activity was determined by measuring the generation of FXa from factor X (FX) (Hemochrom Diagnostica, Essen, Germany) using 200 mol/L chromogenic substrate N-␣-benzyloxycarbonyl-D-arginyl-glycyl-L-arginine-p-nitroaniline (S-2765, Hemochrom Diagnostica). After stimulation of cells in 96-well plates with test substances for the indicated times, they were washed with Hepes-buffered saline and incubated for 15 minutes at 37°C with FVIIa (2 nmol/L) (Hemochrom Diagnostica), FX (75 nmol/L), and aprotinin (1.5 mol/L) in Hepes-buffered saline-CaCl 2 (3 mmol/L) with 0.3% bovine serum albumin (wt/vol). Thereafter the chromogenic substrate for FXa, S-2765 (200 mol/L) was added and FXa was quantified as increase in absorbance (405 nm) with time (maximal reaction velocity) (BioTek Instruments, Winooski, Vermont). Final reaction volume was 50 L, and standard concentrations of FXa (Hemochrom Diagnostica) were run to quantify the levels of FXa generated.
Measurement of TFPI Activity in Cell Supernatants and Solutions
TFPI inhibition of FX activation by FVIIa/TF was measured in a 2-stage assay with a chromogenic substrate by a slightly modified method of Sandset et al. 31 In the first stage, cell-conditioned medium, with aprotinin (1.5 mol/L), was incubated for 15 minutes at 37°C with TF-phospholipid preparation (Innovin or Thromborel S), FVIIa (0.2 nmol/L), FXa (0.8 nmol/L), and CaCl 2 (15 mmol/L) in 25 mmol/L Tris/HCl, pH 7.5, containing 100 mmol/L NaCl, 10 mmol/L trisodium citrate, and 0.2% bovine serum albumin (wt/vol). In the second stage, 25 L of FX (85 nmol/L) was added, and FXa generated in the reaction mixture was measured with S-2765 (200 mol/L) as a substrate.
TFPI activity released by the human umbilical vein endothelial cells (HUVECs) was also quantified with an Actichrome TFPI activity assay following the manufacturer's instructions (American Diagnostica). In brief, this assay measures, in TFPI-depleted plasma, the ability of TFPI in a test sample to inhibit the activation of FX by the TF/FVIIa complex. A dilution of a TFPI reference standard in TFPI-depleted plasma serves as calibration curve.
Cell Culture
HUVECs were isolated using collagenase and cultivated on collagencoated dishes (5 g/mL) with endothelial basal medium (PromoCell, Heidelberg, Germany), containing hydrocortisone (1 g/mL), epidermal growth factor (10 ng/mL), basic fibroblast growth factor (10 ng/mL), and fetal calf serum (5% vol/vol). For the complete study, cells from Ϸ25 donors at passages 2 to 4 were used. Cells in 96-well plates were stimulated with test substances in serum-free medium. Cells were stimulated with TNF␣ (25 ng/mL) for 5 to 6 hours.
Western Blots
Cells were lysed in SDS-containing buffer, and separation of polypeptides was performed by SDS-PAGE under reducing (10% vol/vol mercaptoethanol) or nonreducing conditions and electrotransferred onto the polyvinylidene difluoride membrane (GE Healthcare, Munich, Germany). Labeling of the transferred protein by primary antibody was done for 16 hours at 4°C in 5% (wt/vol) skim milk in tris-buffered saline-Tween 20 (0.1% vol/vol). Secondary horseradish peroxidase-conjugated antibody against primary antibody was incubated for 1 hour at room temperature. Detection of the horseradish peroxidase signal was performed by ECL Plus Western Blotting Detection Reagents (GE Healthcare).
Processing of TFPI by FSAP in Solution
Recombinant TFPI was incubated with FSAP, and TFPI was analyzed by Western blotting. In other experiments, cleaved TFPI was transferred to polyvinylidene difluoride membranes and subjected to N-terminal sequencing (Applied Biosystems, Darmstadt, Germany) for the determination of the cleavage sites.
After treatment of recombinant TFPI (12.5 nmol/L) with WT-and MI-FSAP, residual TFPI activity was measured with a TFPI chromogenic activity assay (Actichrome, American Diagnostica). Alternatively, the activity of FSAP-treated TFPI was measured as diluted prothrombin time. The test solution was diluted 1:10 in TFPIdepleted plasma (containing 10 mol/L aprotinin), and 20 L was mixed with 100 L imidazole and 30 L of PTT reagent (Thromborel S, prediluted 1:1000 in imidazole). The mixture was incubated for exactly 3 minutes at 37°C. Finally, 50 L of 20 mmol/L CaCl 2 was added, and clot formation was measured at 405 nm for 15 minutes at 37°C. In all solutions, 10 mol/L aprotinin was present to prevent any FSAP activity during the assay. The diluted prothrombin time is defined as the time when 50% of maximum absorption is reached.
FSAP Binding to TFPI
Recombinant full-length TFPI or truncated 2-domain TFPI(1-160) was coated (5 g/mL), and the binding of FSAP (concentration dependence) was investigated. Binding studies were performed in tris-buffered saline with Ca 2ϩ (2 mmol/L). In each case, control binding to bovine serum albumin-coated wells was determined and accounted for when calculating the specific binding. Binding was detected with specific antibodies against FSAP (Mab 1189) followed by horseradish peroxidase-coupled secondary anti-mouse antibody. Similar results were obtained when biotinylated PPACK-FSAP was used as a ligand, and binding was detected with streptavidinhorseradish peroxidase.
Statistical Analysis
Results are shown as meanϮSD from triplicate wells. All in vitro data were replicated in at least 3 times, and similar results were obtained in 3 independent experiments. Where indicated, statistical significance was analyzed by ANOVA followed by the Bonferroni post test.
Results
Regulation of FXa Generation On HUVECs by FSAP
We investigated whether FSAP influences TF/FVIIamediated FXa formation on activated-endothelial cells using FVIIa. HUVECs were prestimulated with TNF␣ for 5 hours to upregulate TF and then further treated with 2-chain FSAP for 1 hour. After the cells were washed and any remaining FSAP activity was inhibited with excess aprotinin, FXa formation on the cell surface was determined.
Incubation of TNF␣-stimulated cells with FSAP further increased FXa generation ( Figure 1A ). The fold increase with FSAP was identical in the presence or absence of TNF␣ (data not shown), but in TNF␣-stimulated cells, the absolute amount of FXa generated was higher. The effect of FSAP on TNF␣stimulated cells was apparent after 5 minutes and maximal after 30 minutes. A significant effect was observed already with 15 nmol/L of FSAP ( Figure 1B ). MI-FSAP had a much weaker effect than WT-FSAP and was in the same range of active site-blocked FSAP, PPACK-FSAP. In different isolates of TNF␣-stimulated HUVECs, a 2-to 4-fold increase in FXa generation with FSAP was observed, and this variation was intrinsic to the different isolates of cells. The synergistic effect between FSAP and TNF␣ could be blocked by an anti-TF, as well as anti-FSAP, blocking antibody, which emphasizes the specificity of this effect ( Figure 1C ). Measurement of FXa generation required the presence of both FVIIa and FX in the incubation mixture, and omission of either resulted in no hydrolysis of the FXa substrate (data not shown). These controls indicated that FSAP did not directly activate FX or cleave the chromogenic substrate S-2765; moreover, the activation of cell-bound/serum-derived FVII by FSAP appeared unlikely.
An increase in TF expression in HUVECs treated with FSAP could account for the above observations. Western blot analysis showed that TF was upregulated by TNF␣, but the addition of FSAP did not influence this (Supplemental Data II). FSAP, in the absence or presence of TNF␣, did not influence the levels of mRNA for TF, thrombomodulin, or TFPI (Supplemental Data III). An increase in the cell surface content of negatively charged phospholipids by FSAP could also account for the increased FXa generation. However, annexin V binding to FSAP-treated cells was unchanged, whereas ionomycin induced a robust increase in annexin V binding (Supplemental Data IV).
Measurable levels of endotoxin (11Ϯ1 pg of endotoxin per 1 g of FSAP, nϭ3 different FSAP preparations) were found in the FSAP preparation, but the use of this concentration of endotoxin did not increase FXa generation on cells (data not shown). All experiments were done in the absence of serum, and under these conditions, the sensitivity of HUVECs to endotoxin is very low. This, together with the antagonistic effect of aprotinin, PPACK, or FSAP-blocking antibody, confirms that the effect of FSAP is not mediated by endotoxin or any other contaminant but by FSAP itself.
Because the increase in FXa generation was not due to upregulation of TF or procoagulant phospholipids, we considered the possibility that FSAP cleaves and inactivates TFPI. To test this hypothesis, Western blot analysis of cell extracts and supernatants from HUVECs were performed with anti-TFPI Ab. FSAP decreased TFPI levels in a concentration-and timedependent manner in cell supernatants and extracts (Figure 2A ; only data for cell extracts are shown). A significant loss of TFPI was seen with FSAP in a time-and concentration-dependent manner (Figure 2A ). PPACK-FSAP did not reduce TFPI levels, whereas MI-FSAP had a weaker effect ( Figure 2B ). This reduction in the levels of TFPI in cell extracts of FSAP-treated cells (cf. Figure 2) was not due to FSAPmediated downregulation of TFPI mRNA expression (Supplemental Data III). Thus, the influence of FSAP on TF-dependent FXa generation on endothelial cells could be correlated with a loss of TFPI protein.
To substantiate this assumption, we investigated whether the loss in TFPI protein leads to the loss of TFPI activity in TFPI-depleted plasma using the Actichrome TFPI chromogenic activity assay. This assay measures the generation of FXa by TF/FVIIa complex in TFPI-depleted plasma relative to a TFPI standard. 32 TFPI activity is shown in plasma U/mL (with 1 U/mL corresponding to 55 ng/mL or 1.4 nmol/L). In the conditioned medium of HUVECs, a TFPI activity of 0.3 U/mL was seen after 2 hours and 0.5 U/mL after 6 hours ( Figure 2C ). Treatment of HUVECs with FSAP for 2 or 6 hours prevented the accumulation of TFPI activity, supporting the hypothesis that TFPI released by the cells is inactivated by FSAP. Because other proteases are known to cleave TFPI, we compared their relative efficacy. On HUVECs, elastase was very effective in cleaving TFPI, followed by activated protein C and FSAP, which was more potent than plasmin, thrombin, and FXa (Figure 3 ).
Characterization of the Interaction Between FSAP and TFPI
Binding studies with isolated proteins were performed to characterize the interaction between FSAP and TFPI. FSAP bound to full-length TFPI but not to the 2-domain form(1-160), which does not have the C-terminal heparin binding domain ( Figure 4A ). We then compared how the 2 forms of TFPI were inhibited by FSAP. TFPI activity was determined by a 2-step FXa generation assay as described before. 31 In a first set of experiments, it was confirmed that recombinant TFPI decreased TF/FVIIa-dependent FX ac-tivation in a dose-dependent manner. With a TFPIblocking Ab, the inhibitory effect of TFPI on FXa generation could be reversed, and FX activation was increased (Supplemental Data V). Similarly, in the concomitant presence of FSAP, the inhibitory effect of TFPI was reversed, and an increase in FX activation was observed. In this experiment, FSAP activity was blocked with excess aprotinin so that this did not interfere with the chromogenic substrate assay for FXa. FSAP had no influence on the assay if TFPI was simultaneously neutralized by anti-TFPI Ab. Hence, in a purified system, FSAP could regulate TFPI activity (Supplemental Data V).
In this assay, full-length TFPI was more effective in inhibiting FXa generation than TFPI(1-160) ( Figure 4B) . When both forms were tested in the presence of FSAP, the full-length TFPI was completely inhibited, whereas the TFPI(1-160) was much less inhibited by FSAP ( Figure 4C ). Hence, the C-terminal heparin binding domain of TFPI is crucial for binding to FSAP and for inactivation of TFPI by FSAP.
We then screened a panel of Mab to identify ones that (1) inhibited the proteolytic activity of FSAP, and (2) blocked the binding of FSAP to TFPI. We used one Mab (Mab 570) that inhibited the enzymatic activity of FSAP ( Figure 4C ) and another Mab (MA-38C7) that blocked the binding of FSAP to TFPI but not its enzymatic activity ( Figure 4D ). Both antibodies could reverse the effect of FSAP on TFPI, indicating that the binding of FSAP to TFPI is important for inhibiting the activity of the latter ( Figure 4E ). Effect of factor VII-activating protease (FSAP) on tissue factor pathway inhibitor (TFPI) in human umbilical vein endothelial cells (HUVECs). A, Cells were treated with FSAP (0 -150 nmol/L) for 120 minutes (left) or with 30 nmol/L FSAP for 0 to 120 minutes (right), and the cell extracts were used for Western blotting using an anti-TFPI antibody (Ab) under nonreducing conditions. B, Cells were treated with PPACK-FSAP, FSAP, and Marburg I (MI)-FSAP at the indicated concentrations for 120 minutes and analyzed as described above. Migration of molecular weight markers and TFPI is indicated. C, Cells were treated in the presence or absence of FSAP for 2 hours (dotted column) or 6 hours (filled column), respectively, and the TFPI activity was measured in an Actichrome TFPI chromogenic activity assay relative to a TFPI reference standard. *PϽ0.05. Figure 3 . Effect of different proteases on tissue factor pathway inhibitor (TFPI) cleavage in activated human umbilical vein endothelial cells (HUVECs). Tumor necrosis factor-␣-stimulated HUVECs were treated for 60 minutes with neutrophil elastase, activated protein C (APC), factor VII-activating protease (FSAP), plasmin, thrombin, and activated factor X (FXa) (0 -90 nmol/L), and cell extracts were examined for TFPI by Western blot (WB) analysis with an anti-TFPI antibody.
The proteolytic cleavage of TFPI was then characterized in further detail. Incubation of recombinant TFPI with FSAP led to the degradation of TFPI in a time-and dose-dependent manner, leading to the disappearance of the TFPI band in SDS-PAGE under nonreducing conditions and the appearance of a lower molecular weight band under reducing conditions ( Figure 5A ). N-terminal sequencing of the smaller peptides arising from the cleavage showed that many of them contained the original N terminus of intact TFPI, indicating multiple sites of proteolytic cleavage ( Figure 5B ). Peptides exhibiting internal TFPI sequences indicated that the cleavage occurred between kringle domains K1 and K2 (Lys86Thr87), as well as in the active site of K2 (Arg107Gly108) and K3 (Arg199Ala200) domains (numbering refers to mature full-length TFPI protein). These sites are nearly identical to those reported previously for plasmin, 24 thrombin, 25 and elastase 26 (Supplemental Data VI). Therefore, TFPI is cleaved at multiple sites by FSAP, leading to its complete inactivation.
Influence of the MI-SNP on TFPI Anticoagulant Function
Recombinant TFPI was incubated with WT-and MI-FSAP and the residual TFPI activity was measured in TFPIdepleted plasma using a TFPI chromogenic activity assay ( Figure 6A ). WT-FSAP was much more effective, reducing TFPI activity by 60%, whereas MI-FSAP under the same conditions did not inactivate TFPI. WT-FSAPtreated TFPI, added to TFPI-depleted plasma, accelerated the diluted prothrombin time by 30 to 40 seconds compared with untreated TFPI, providing evidence that FSAP can inhibit TFPI activity in plasma ( Figure 6B ). As could be expected from the preceding results, the effect of for FSAP (Hemochrom Diagnostica) and was followed over a period of 60 minutes at 37°C at 405 nm in a microplate reader. FSAP was preincubated with the Mab (10 g/mL) for 30 minutes before addition of the chromogenic substrate. FSAP activity is shown as maximal velocity (meanϮSD) in ⌬mOD/min. D, The effect of a panel of anti-FSAP Mab on FSAP binding to TFPI was tested. Mab were added (10 g/mL) to immobilized TFPI, and then biotinylated PPACK-FSAP binding was determined. E, Effect of a panel of anti-FSAP Mab on the modulation of TFPI activity by FSAP. In an FXa generation assay, the effect of TFPI, as well as FSAP, separately or together, was determined in the absence or presence of the indicated Mab as described in the figure. *PϽ0.05. Figure 5 . Characterization of the cleavage of recombinant tissue factor pathway inhibitor (TFPI) by factor VII-activating protease (FSAP). A, Cleavage of recombinant TFPI by FSAP was followed by Western blotting. In the left panels, TFPI (14 nmol/L) was incubated with increasing concentrations of FSAP (0 -6 nmol/L) as indicated for 30 minutes. Western blots were performed with an anti-TFPI polyclonal antibody under nonreducing conditions (NR) or after reduction (R) of samples. In the right panels, TFPI (14 nmol/L) was incubated with FSAP (1.5 nmol/L) for the indicated times, and Western blots were performed. Migration of molecular weight markers and TFPI, as well as a degradation fragment, is indicated with arrows. B, Determination of the cleavage sites in TFPI. TFPI and FSAP were incubated for 30 minutes at 37°C as indicated, run on SDS-PAGE gels, and blotted on to a polyvinylidene difluoride membrane. This was stained with Coomassie Blue, and the protein bands were subjected to aminoterminal sequencing using an automated Edman sequencer (Applied Biosystems). Numbers refer to position of amino acid in full-length mature TFPI protein.
MI-FSAP on TFPI activity in plasma was weaker ( Figure  6B ). These results demonstrate that the cleavage of TFPI by FSAP also inhibits TFPI function in plasma, leading to accelerated coagulation, and show that the MI variant is much weaker in this respect.
Discussion
About 10 years ago, FVII activation was shown to be a key function of FSAP. 2 However, there have been no further studies confirming these findings. We found a concentration-dependent increase in FVIIa on treatment of purified FVII with the WT-FSAP, but not more than 4% of FVII could be activated, similar to previously published data. 8 Supraphysiological concentrations of FSAP were needed for FVII activation, confirming that FVII is indeed a weak substrate of FSAP. MI-FSAP was even worse and did not activate FVII, in contrast to earlier reports. 8 This pattern was exactly similar to what we had previously reported for prourokinase activation. 20 Our search for another substrate relevant in extrinsic coagulation led to the finding that TFPI is a novel substrate for FSAP. Direct compar-ison shows that the EC 50 for FVII activation by FSAP was in the range 100 nmol/L, whereas the EC 50 for TFPI inactivation was Ϸ3 nmol/L. TFPI is a key factor in determining the threshold for the initiation of the extrinsic pathway of blood coagulation. 21 FSAP can inactivate TFPI, thus altering the balance in favor of FX activation. Although procoagulant effects of FSAP have been mainly attributed to FVII activation in plasma, 2 the effect of FSAP on TFPI degradation likely plays an equally important role in specifically supporting the initiation of the TF pathway of coagulation.
Proteolytic inactivation of TFPI by plasmin, 24 thrombin, 25 elastase, 26 and activated protein C 27 has been reported, and there is evidence for truncated TFPI in the circulation. The generation of smaller TFPI fragments by FSAP with an intact original N terminus indicates truncation in the direction of the C terminus, similar to that described for other proteases. It is likely that cleavage at multiple locations leads to a cumulative loss of TFPI activity. A comparison of these proteases showed that elastase and activated protein C were more effective than FSAP, which in turn was more effective than plasmin, thrombin, and FXa. There was a difference in the sensitivity of TFPI to FSAP in Western blots using purified proteins compared with that of TFPI in activity assays in HUVECs. It is likely that protease inhibitors bound to the HUVEC surface and in the conditioned medium may also account for the inhibition of exogenously added FSAP and increase the effective concentration required for TFPI inactivation on cells as compared with the purified system.
FSAP binds strongly to nucleic acids, 33 histones, 6 and postapoptotic cells/nucleosomes 5 and is activated in plasma by factors released from dead cells. 5, 6 Recently, TFPI was shown to bind strongly to neutrophil-derived nucleic acid/nucleosomes (neutrophil extracellular trap) and was inactivated by neutrophil elastase that also binds to nucleosomes. 29 Under such circumstances, the restricted localization of the substrate (TFPI) and the protease (FSAP) on a common surface may achieve conditions that favor TFPI cleavage by FSAP. Although the concentrations of other TFPI-inactivating proteases, such as thrombin, plasmin, or elastase, are higher in the circulation, in specialized niches that are rich in nucleic acids/nucleosomes, active FSAP may reach significant levels and contribute to TFPI inactivation.
Our observation that FSAP inhibits the full-length 3-domain TFPI efficiently but not the 2-domain form has fundamental implications for future work in this area. Strong species differences in the expression of different TFPI isoforms exist in humans and mice such that adult mice express predominantly the 2-domain TFPI-␤ and humans the 3-domain TFPI-␣. 23, 29 This would suggest that any influence of FSAP on mouse TFPI is not to be expected.
Although the presented data show that FSAP regulates the activity of TFPI in clotting assays, FSAP may also regulate the signaling functions of TF. TFPI is also involved in regulating restenosis and atherosclerosis, 28, 34 and the same is true for FSAP. 20 It is intriguing that TF-dependent angiogenesis is dependent on platelet-derived growth factor-BB 35 and suppressed by inhibitors with a functional mechanism analogous to TFPI 36 . Because FSAP directly regulates platelet-derived growth factor-BB and activates the TF-associated proteases involved in cell signaling, it is conceivable that FSAP plays a critical role in fine-tuning these noncoagulant aspects of the hemostatic system in vascular remodeling processes.
